The U.S. Senate on Wednesday confirmed Ronald Johnson, a former ambassador to El Salvador, as ambassador to Mexico, amid ties ...

The Dark Secrets of Johnson & Johnson,” veteran reporter Gardiner Harris scrutinizes the legacy of health care giant Johnson ...

A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it ...

If the FDA approves nipocalimab, the long-term data could form part of J&J’s pitch for the gMG market. The labels for ...

Nearly a year after a jury decided that Johnson & Johnson should be fined just over $150 million in a lawsuit alleging that ...

Officials at the Department of Health and Human Services have struggled to find records belonging to Dr. Tom Shimabukuro, the ...

The Dark Secrets of Johnson & Johnson.” Erythropoietin — also known as EPO — is mostly remembered as the drug that cyclist Lance Armstrong dishonestly used to win seven Tours de France.

Johnson & Johnson's long-term prospects are promising due to strong drug pipeline developments and significant R&D ...

Boston Scientific Corp.’s up to $664 million acquisition of Bolt Medical Inc. closed just days after Bolt secured U.S. FDA 520(k) clearance for its intravascular lithotripsy (IVL) system, positioning ...

Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya (guselkumab), to treat moderately to severely active Crohn's disease ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the first and only IL-23 inhibitor offering subcutaneous (SC) and ...

Johnson & Johnson announced that the U.S. FDA has granted investigational nipocalimab Fast Track designation for the treatment of adult patients with moderate-to-severe Sjogren’s disease ...